Novavax RSV vaccine performs well in early stage trial

|By:, SA News Editor

Novavax's (NVAX +1.5%) vaccine for respiratory syncytial virus (RSV), which causes infections of the lungs and breathing passages, performed well in a Phase I trial of 220 healthy adults aged 60 years and older.

The RSV F vaccine was compatible when administered with a flu vaccine, was well-tolerated, and it helped increase antibodies with potentially protective effects. (PR)